ASCO Preview: Five Presentations To Watch Out For

AstraZeneca’s data showcase its grand strategy in lung cancer, while a trial from Gilead could provide valuable learnings for anti-TROP2 antibodies as they become more competitive - not only on efficacy, but also on safety. J&J and Legend, meanwhile, are nipping at BMS and 2seventy’s heels.